Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.

Springerplus · 2015 · PMC4429427 · PMID 25995984

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

just failed to reach significancep = 0.056so close (0.05 < p ≤ 0.1)

In our study, capecitabine significantly improved the 4-year DFS (p = 0.016), but the OS just failed to reach significance (p = 0.056), probably due to the small number of deaths.

also in 279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.